Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

Int J Cancer. 1999 Jan 18;80(2):219-30. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s.


Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigen Presentation
  • Antigens, Neoplasm / adverse effects
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / therapeutic use*
  • Disease Progression
  • Female
  • Genetic Code
  • HLA-A1 Antigen / immunology*
  • Humans
  • Immunotherapy*
  • Male
  • Melanoma / secondary
  • Melanoma / therapy*
  • Middle Aged
  • Neoplasm Proteins / adverse effects
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / therapeutic use*
  • Remission Induction / methods*


  • Antigens, Neoplasm
  • HLA-A1 Antigen
  • MAGEA3 protein, human
  • Neoplasm Proteins